Polarean Imaging PLC

Polarean has submission for US approval and completion of trials 'clearly in its sights'

Richard Hullihen, CEO of Polarean Imaging PLC (LON:POLX), brings Proactive London's Andrew Scott up to date on developments since their IPO back in March.

The company's recently raised US$4mln to complete their clinical trials and submit an NDA for the FDA.

''We're very happy to now have that clearly in our sights and a straight run through to completion on the trials'', Hullihen says.

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...



Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago


Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago

2 min read